芪胶升白胶囊治疗消化道恶性肿瘤化疗后骨髓抑制临床效果与安全性观察  

Clinical Effect and Safety Observation of Qijiao Shengbai Capsule(芪胶升白胶囊)on Bone Marrow Suppression after Chemotherapy for Digestive Tract Malignant Tumor

作　　者：李燕[1] 陈蓉[1] 徐新倩 LI Yan;CHEN Rong;XU Xinqian(Affiliated Hospital of Qinghai University,Xining 810000,Qinghai,China)

机构地区：[1]青海大学附属医院,青海西宁810000

出　　处：《中华中医药学刊》2023年第7期235-238,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：青海省科技厅应用基础研究项目(2020-ZJ-782)。

摘　　要：目的 观察消化道恶性肿瘤化疗后骨髓抑制采取芪胶升白胶囊治疗临床效果与安全性。方法 研究纳入消化道恶性肿瘤化疗后骨髓抑制患者合计96例(2021年2月-2022年4月收治),将其以随机数字表法分成对照组和观察组,各48例。对照组患者实施化疗治疗+重组人粒细胞集落刺激因子治疗,观察组化疗治疗同时结合重组人粒细胞集落刺激因子及芪胶升白胶囊治疗。两组数据对比:疗效、白细胞减少继发感染率、治疗前后中医证候积分(食少纳呆、神疲乏力、头晕心悸、面色无华及少气懒言、自汗盗汗等)变化、血常规指标变化、免疫指标变化、生活质量量表(KPS)评分变化、不良反应。结果 观察组患者治疗后总有效率(97.92%,47/48)高于对照组(85.42%,41/48)(P<0.05);观察组患者白细胞减少继发感染率(4.17%,2/48)低于对照组(16.67%,8/48)(P<0.05);治疗前,两组患者中医证候积分(食少纳呆、神疲乏力、头晕心悸、面色无华及少气懒言、自汗盗汗等)、白细胞计数(WBC)、血小板(PLT)、血红蛋白(Hb)等血常规指标、免疫球蛋白A(IgA)、免疫球蛋白M(IgM)、免疫球蛋白G(IgG)等免疫指标、KPS评分比较,P>0.05,治疗后各组患者中医证候积分(食少纳呆、神疲乏力、头晕心悸、面色无华及少气懒言、自汗盗汗等)、WBC、PLT、Hb、IgA、IgM、IgG、KPS评分等指标均改善,观察组患者治疗后中医证候积分(食少纳呆、神疲乏力、头晕心悸、面色无华及少气懒言、自汗盗汗等)、WBC、PLT、Hb、IgA、IgM、IgG、KPS评分等指标均比对照组更佳(P<0.05);对照组患者不良反应率(2.08%,1/48)与观察组(4.17%,2/48)比较,P>0.05。结论 消化道恶性肿瘤化疗后骨髓抑制采取芪胶升白胶囊治疗临床效果较好,可降低患者白细胞减少继发感染率,提升患者生活质量与免疫能力,不良反应率低,安全可靠。Objective To observe the clinical effect and safety of Qijiao Shengbai Capsule(芪胶升白胶囊)in the treatment of bone marrow suppression after chemotherapy for digestive tract malignant tumor.Methods A total of 96 patients with myelosuppression after chemotherapy for gastrointestinal malignancies(admitted from February 2021 to April 2022)were included in this study.They were divided into control group and observation group by random number table method,with 48 cases in each group.Patients in the control group were treated with chemotherapy plus recombinant human granulocyte colony stimulating factor,while those in the observation group were treated with chemotherapy combined with recombinant human granulocyte colony stimulating factor and Qijiao Shengbai Capsule.The curative effect,secondary infection rate of leukopenia,changes in TCM syndrome scores before and after treatment(lack of appetite,fatigue,dizziness and palpitation,dull complexion,lack of breath and lazy speech,spontaneous sweating and night sweating,etc.),changes in blood routine indexes,immune indexes,changes in Karnofsky(KPS)score and adverse reactions of two groups were observed.Results The total effective rate of the observation group(97.92%,47/48)was higher than that(85.42%,4/48)of the control group(P<0.05).The secondary infection rate of leukopenia in the observation group(4.17%,2/48)was lower than that(16.67%,8/48)in the control group(P<0.05).Before treatment,the comparison of TCM syndrome scores(lack of appetite,fatigue,dizziness and palpitation,dull complexion,lack of breath and lazy speech,spontaneous sweating and night sweating,etc.),white blood cell count(WBC),platelet(PLT),hemoglobin(Hb)and other blood routine indicators,immunoglobulin A(IgA),immunoglobulin M(IgM),immunoglobulin G(IgG)and other immune indicators and KPS scores of two groups had no significance(P>0.05).After treatment,the TCM syndrome scores(lack of appetite,fatigue,dizziness and palpitation,dull complexion,lack of breath and lazy speech,spontaneous sweating and nigh

关 键 词：消化道恶性肿瘤 化疗 骨髓抑制 芪胶升白胶囊 疗效 白细胞减少继发感染 不良反应 

分 类 号：R273.35[医药卫生—中西医结合]